The B7–CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system
DE Anderson, AH Sharpe, DA Hafler - Current opinion in immunology, 1999 - Elsevier
DE Anderson, AH Sharpe, DA Hafler
Current opinion in immunology, 1999•ElsevierThe past year has seen significant advances in our understanding of the role of the B7–
CD28/CTLA-4 pathway in regulating the responses of self-reactive T cells, giving impetus to
manipulation of this pathway for treating human autoimmune diseases. Recent studies have
demonstrated that B7–CD28 costimulation has critical roles in stimulating both the initiation
and effector phases of autoimmunity and that CD28 regulates the threshold for activation of
self-reactive T cells. Recent work has also revealed critical roles for CTLA-4 in limiting the …
CD28/CTLA-4 pathway in regulating the responses of self-reactive T cells, giving impetus to
manipulation of this pathway for treating human autoimmune diseases. Recent studies have
demonstrated that B7–CD28 costimulation has critical roles in stimulating both the initiation
and effector phases of autoimmunity and that CD28 regulates the threshold for activation of
self-reactive T cells. Recent work has also revealed critical roles for CTLA-4 in limiting the …
The past year has seen significant advances in our understanding of the role of the B7–CD28/CTLA-4 pathway in regulating the responses of self-reactive T cells, giving impetus to manipulation of this pathway for treating human autoimmune diseases. Recent studies have demonstrated that B7–CD28 costimulation has critical roles in stimulating both the initiation and effector phases of autoimmunity and that CD28 regulates the threshold for activation of self-reactive T cells. Recent work has also revealed critical roles for CTLA-4 in limiting the extent of Th1/Th2 cell differentiation and in downregulating the responses of self-reactive T cells during both the initiation and progression of autoimmune disease.
Elsevier